

Section 1: Issuer information (mandatory)				
Name of issuer	Rua Bioscience Limited			
Class of Financial Product	Ordinary shares			
NZX ticker code	RUA			
ISIN (If unknown, check on NZX website)	NZRUAE0004S1			
Name of Registry	Computershare Investor Services Limited			
Type of corporate action (Please mark with an X in the relevant box/es)	Share Purchase Plan/retail offer		Renounceable Rights issue or Accelerated Offer	X
	Capital reconstruction		Non-Renounceable Rights issue or Accelerated Offer	
	Call		Bonus issue	
	Placement			
Record date	13/11/2024			
Ex Date (one business day before the Record Date)	12/11/2024			
Currency	NZD			
External approvals required before offer can proceed on an unconditional basis?	N			
Details of approvals required	N/A			
Section 2: Rights issue or Accelerated Offer (delete full section if not applicable, or mark rows as N/A if not applicable)*				
If Accelerated Offer, structure	N/A (not an Accelerated Offer)			
Number of Rights to be issued or entitlements available for security holders in the Accelerated Offer	N/A (not an Accelerated Offer)			
Maximum number of Equity Securities to be issued if offer is fully subscribed	Approximately 122,789,125 (subject to rounding)			
ISIN of Rights (if applicable)	NZRUAE0005S8			
Oversubscription facility	Y. New shares not taken up by eligible shareholders in the rights issue will be offered through an oversubscription facility. Eligible shareholders who take up their rights in full have the opportunity to apply for additional new shares in the oversubscription facility.			

Details of scaling arrangements for oversubscriptions	<p>If demand for New Shares were to exceed availability, applicants participating in the Oversubscription Facility will be subject to scaling on a pro rata basis (by reference to existing holdings on the Record Date).</p> <p>Rua reserves the right to place any subsequent shortfall in accordance with the NZX Listing Rules.</p>			
<p>Entitlement ratio (for example 1 for 3)</p> <p>Please contact NZX ahead of announcing the offer if each Right will be exercisable for more or less than one Equity Security (i.e unless prior arrangement is made, Rights will be exercisable on a one for one basis)</p>	New		Existing	
	3	For	4	
Treatment of fractions**	Where fractions arise in the calculation of rights, they will be rounded down to the nearest right			
Subscription price (per Equity Security)	\$0.025			
Letters of entitlement mailed	14/11/2024			
Offer open	14/11/2024			
Offer close	26/11/2024			
Quotation date (if Rights will be quoted)	Market for rights trading open on: 12/11/2024			
Allotment date	2/12/2024			
Section 8: Lead Manager and Underwriter (mandatory)				
Lead Manager(s) appointed	Y			
Name of Lead Manager(s)	Northington Partners Limited			
Fees, commission or other consideration payable to Lead Manager(s) for acting as lead manager(s)	Rua agrees to pay a lead management fee of 8.5% of the total gross proceeds raised under the rights offer.			
Underwritten	N			
Name of Underwriter(s)	N/A			
Extent of underwriting (i.e. amount or proportion of the offer that is underwritten)	N/A			
Fees, commission or other consideration payable to Underwriter(s) for acting as underwriter(s)	N/A			
Summary of significant events that could lead to the underwriting being terminated	N/A			
Section 9: Authority for this announcement (mandatory)				
Name of person authorised to make this announcement	Paul Naske			

Contact person for this announcement	Paul Naske
Contact phone number	021 445 154
Contact email address	paul.naske@ruabio.com
Date of release through MAP	6/11/2024